Down-regulation of the MiRNA Master Regulators Drosha and Dicer is Associated with Specific Subgroups of Breast Cancer
Overview
Authors
Affiliations
Down-regulation of Drosha and Dicer has been suggested to be of prognostic value in some cancers. The aims of our study were to investigate the down-regulation of Drosha and Dicer in breast cancers and its associations with clinicopathological features, molecular subtypes and outcome. Drosha and Dicer expression was assessed with real-time RT-PCR in 245 patients with breast cancer receiving adjuvant anthracycline-based chemotherapy and compared to expression levels of normal breast tissue. Drosha down-regulation was observed in 18% of cases and was associated with high grade, high Ki-67, lack of Bcl2 expression, HER2 over-expression and gene amplification and TOPO2A gene amplification. Dicer down-regulation was found in 46% of cases and was associated with lack of expression of ER, PR and Bcl2 and with high grade, high Ki-67, triple-negative and basal-like phenotypes. Drosha and Dicer were concurrently down-regulated in 15% of cases and significantly associated with high grade and high Ki-67 index. No significant associations between down-regulation of Drosha and/or Dicer and outcome were observed. Our results suggest that down-regulation of Drosha and/or Dicer is not robustly associated with the outcome of breast cancer patients treated with adjuvant anthracycline-based chemotherapy but preferentially observed in distinct subgroups of breast cancer.
Technologies for Targeted RNA Degradation and Induced RNA Decay.
Mikutis S, Bernardes G Chem Rev. 2024; 124(23):13301-13330.
PMID: 39499674 PMC: 11638902. DOI: 10.1021/acs.chemrev.4c00472.
Encarnacion-Medina J, Godoy L, Matta J, Ortiz-Sanchez C Cells. 2023; 12(9).
PMID: 37174739 PMC: 10177092. DOI: 10.3390/cells12091339.
Dicer Suppresses Hepatocellular Carcinoma via Interleukin-8 Pathway.
Han X, Wu J, Sha Z, Lai R, Shi J, Mi L Clin Med Insights Oncol. 2023; 17:11795549231161212.
PMID: 37056297 PMC: 10088407. DOI: 10.1177/11795549231161212.
Pan-Cancer Study on Variants of Canonical miRNA Biogenesis Pathway Components: A Pooled Analysis.
Elshazli R, Toraih E, Hussein M, Ruiz E, Kandil E, Fawzy M Cancers (Basel). 2023; 15(2).
PMID: 36672288 PMC: 9856462. DOI: 10.3390/cancers15020338.
Predictive and Prognostic Value of Non-Coding RNA in Breast Cancer.
Sobhani N, Chahwan R, Roudi R, Morris R, Volinia S, Chai D Cancers (Basel). 2022; 14(12).
PMID: 35740618 PMC: 9221286. DOI: 10.3390/cancers14122952.